Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. —A five-day workshop in Washington, D.C., It will retain the PixarBio name and aims to start trading on the over-the-counter market during the second week of September.
40 
Let's personalize your content